Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

Key Takeaways

• Dan Mandoli joins Omnicell as SVP, General Manager, Specialty Pharmacy
• Over 30 years leading specialty pharmacy for Fortune 50 and PE firms
• Previously COO of Altruix; led Elevance Health’s specialty pharmacy expansion
• Role focuses on scaling Omnicell’s 340B and specialty pharmacy services
• Aims to boost clinical outcomes and revenue growth for health systems

Pulse Analysis

The specialty pharmacy market is entering a rapid expansion phase, driven by high‑cost, targeted therapies that require sophisticated distribution and adherence support. Health systems are increasingly turning to technology partners that can automate dispensing, manage inventory, and provide analytics to meet the complex regulatory landscape of the 340B drug pricing program. Omnicell, known for its AI‑enabled medication management solutions, is well‑positioned to capture this demand, but scaling its services requires seasoned operational leadership.

Dan Mandoli’s résumé aligns precisely with those needs. With more than 30 years steering specialty pharmacy units at industry giants such as Express Scripts, Elevance Health, and Altruix, he has a proven record of integrating acquisitions, building infrastructure, and driving revenue growth. His recent tenure as COO of Altruix saw measurable improvements in operational efficiency and market share, underscoring his ability to translate strategic vision into execution. By joining Omnicell, Mandoli adds deep market insight and a network of relationships that can accelerate the company’s go‑to‑market strategy for both specialty and 340B services.

Investors and health‑system customers will likely view the appointment as a catalyst for Omnicell’s next growth chapter. Strengthening the specialty pharmacy franchise not only diversifies revenue beyond traditional automation hardware but also deepens the firm’s data‑driven service offerings, which are increasingly valued for improving patient outcomes and cost containment. As the 340B program expands and payer pressure mounts, Omnicell’s ability to deliver integrated, autonomous solutions could translate into higher contract wins and stronger long‑term margins. Mandoli’s leadership is expected to fast‑track these objectives, positioning Omnicell as a go‑to partner in the evolving specialty pharmacy ecosystem.